Fundamental Analysis of VERA THERAPEUTICS INC(NASDAQ:VERA) stock

Fundamental Rating

We assign a fundamental rating of 1 out of 10 to VERA. VERA was compared to 588 industry peers in the Biotechnology industry. VERA may be in some trouble as it scores bad on both profitability and health. VERA is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year VERA has reported negative net income.

VERA had a negative operating cash flow in the past year.

In the past 5 years VERA always reported negative net income.

VERA had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

With a Return On Assets value of -54.68%, VERA perfoms like the industry average, outperforming 46.58% of the companies in the same industry.

With a Return On Equity value of -94.39%, VERA perfoms like the industry average, outperforming 47.60% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-54.68%
ROE	-94.39%
ROIC	N/A

ROA(3y)-53.81%

ROA(5y)-95.74%

ROE(3y)-85.69%

ROE(5y)-140.41%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for VERA so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

Compared to 1 year ago, VERA has more shares outstanding

VERA has a worse debt/assets ratio than last year.

2.2 Solvency

VERA has a Debt/Equity ratio of 0.49. This is a healthy value indicating a solid balance between debt and equity.

VERA has a Debt to Equity ratio of 0.49. This is in the lower half of the industry: VERA underperforms 72.60% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.49
Debt/FCF	N/A
Altman-Z	N/A

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

VERA has a Current Ratio of 7.71. This indicates that VERA is financially healthy and has no problem in meeting its short term obligations.

VERA has a Current ratio of 7.71. This is in the better half of the industry: VERA outperforms 71.58% of its industry peers.

A Quick Ratio of 7.71 indicates that VERA has no problem at all paying its short term obligations.

The Quick ratio of VERA (7.71) is better than 71.75% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	7.71
Quick Ratio	7.71

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 31.04% over the past year.

EPS 1Y (TTM)31.04%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q49.15%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Revenue growth Q2QN/A

3.2 Future

VERA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 21.23% yearly.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y4.62%

EPS Next 2Y-1.32%

EPS Next 3Y-5.48%

EPS Next 5Y21.23%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for VERA. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VERA. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

VERA's earnings are expected to decrease with -5.48% in the coming years. This may justify a cheaper valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-1.32%

EPS Next 3Y-5.48%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for VERA!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

VERA THERAPEUTICS INC

NASDAQ:VERA (4/22/2024, 7:00:03 PM)

After market: 39.13 0 (0%)

39.13

+1.13 (+2.97%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap2.13B

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-54.68%
ROE	-94.39%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset TurnoverN/A

Health

		Industry Rank	Sector Rank
Debt/Equity	0.49
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	7.71
Quick Ratio	7.71
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)31.04%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y4.62%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

VERA THERAPEUTICS INC (VERA)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens